AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 FEB 13 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Enzyme-linked immunospot (ELISPOT) testing can be used to measure the effectiveness of HIV and other vaccines, researchers in the United States report.
"As progress is made towards developing a safe and effective HIV vaccine, there is a need for a robust, sensitive and reproducible assay to evaluate vaccine-induced cellular immunogenicity in Phase II/III trials," according to Jeffrey R. Currier and colleagues at the United States Military HIV Research Program in Rockville, Maryland, Duke University in Durham, North Carolina, and Zellnet Consulting, Inc., in New York City.
ELISPOT assays can fulfill this need, especially since the development of automated readers for analyzing ELISPOT results makes high-volume screening feasible, Currier and coauthors said.
ELISPOT was used to measure gamma interferon (IFN-(gamma)) release from peripheral blood mononuclear cells (PBMCs). The researchers incubated these cells with a group of 23 epitopes from Epstein Barr virus, cytomegalovirus, and influenza viruses, presented by a group of 11 common human leukocyte antigen (HLA) alleles, according to their report.
Most PBMCs produced IFN-(gamma) after exposure to individual epitopes or the set of 23 peptides, whether the cells came from HIV[superscript]+ or healthy volunteers. This IFN-(gamma) release was HLA restricted and mediated by cytotoxic T lymphocytes (CTLs), study data showed.
IFN-(gamma) ...
Source: HighBeam Research, ELISPOT Testing Can Help Determine Cellular Response.(Brief Article)